influenza
contagi
acut
respiratori
viral
diseas
character
short
incub
period
high
fever
respiratori
eg
runni
stuffi
nose
system
symptom
eg
muscl
bodi
ach
peopl
affect
influenza
recov
day
week
howev
patient
may
develop
complic
may
seriou
common
complic
bronchiti
pneumonia
ear
infect
etc
peopl
underli
diseas
asthma
subject
chronic
obstruct
pulmonari
diseas
copd
individu
heart
diseas
high
risk
complic
relat
complic
myositi
acut
encephalopathi
rey
syndrom
rare
rey
syndrom
classic
character
rash
vomit
liver
damag
typic
occur
viral
ill
children
take
aspirin
long
period
pneumonia
caus
bacteri
superinfect
also
call
secondari
pneumonia
viral
pneumon
character
complex
interact
hostcoinfect
pathogen
particularli
frail
debilit
subject
result
impair
physic
capabl
dysregul
immun
respons
delay
return
homeostasi
burden
influenza
heavi
inde
world
health
organ
estim
annual
epidem
affect
world
popul
caus
million
sever
case
death
european
centr
diseas
prevent
control
ecdc
estim
approxim
european
infect
year
furthermor
us
govern
estim
us
resid
catch
influenza
year
influenza
virus
belong
ortomyxovirida
famili
two
genera
isaviru
thogotoviru
abil
chang
surfac
antigen
rel
frequent
major
variat
occur
viru
adapt
human
zoonot
spillov
widespread
diffus
viru
possibl
result
pandem
sever
influenza
pandem
caus
million
case
million
death
devast
pandem
treatment
patient
suffer
influenza
empir
symptomat
intend
primarili
reliev
fever
pain
eg
aspirin
administr
epinephrin
use
treat
form
secondari
pneumonia
first
antivir
drug
influenza
name
amantadin
becom
avail
us
anoth
drug
rimantadin
author
later
antineuraminidas
na
medic
zanamivir
oseltamivir
licens
us
influenza
virus
belong
ortomyxovirida
famili
two
genera
isaviru
thogotoviru
abil
chang
surfac
antigen
rel
frequent
major
variat
occur
viru
adapt
human
zoonot
spillov
widespread
diffus
viru
possibl
result
pandem
sever
influenza
pandem
caus
million
case
million
death
devast
pandem
treatment
patient
suffer
influenza
empir
symptomat
intend
primarili
reliev
fever
pain
eg
aspirin
administr
epinephrin
use
treat
form
secondari
pneumonia
first
antivir
drug
influenza
name
amantadin
becom
avail
us
anoth
drug
rimantadin
author
later
antineuraminidas
na
medic
zanamivir
oseltamivir
licens
us
sinc
much
knowledg
concern
viral
replic
acquir
new
experiment
hypothes
advanc
develop
new
flu
drug
new
protocol
prevent
treatment
antiinfluenza
drug
import
complement
vaccin
efficaci
weapon
diseas
review
therefor
seem
use
deal
issu
newpotenti
antivir
medic
influenza
infect
especi
light
recent
scientif
advanc
regard
antigen
characterist
core
protein
nucleoprotein
np
matrix
protein
protein
three
influenza
viru
type
identifi
b
c
given
relev
influenza
viru
iav
human
patholog
provid
brief
overview
biolog
lifecycl
underlin
main
differ
among
three
viru
type
term
structur
molecular
biolog
iav
particl
vari
rang
nm
pleomorph
usual
spheric
though
cordlik
form
diamet
nm
length
rang
occur
transit
spheric
tubular
form
well
understood
known
far
np
could
play
role
determin
modul
process
besid
genet
trait
also
phenotyp
host
cell
term
shape
polar
seem
influenc
viral
form
influenza
b
similar
shape
structur
indistinguish
iav
influenza
c
viru
usual
filament
nm
long
iav
viral
particl
envelop
made
lipid
raft
spike
two
main
type
glycoprotein
hemagglutinin
ha
account
molecul
na
molecul
least
abund
protein
copi
per
virion
particl
influenza
b
viru
contain
four
protein
name
ha
na
nb
particl
influenza
c
viru
made
major
surfac
glycoprotein
hef
hemagglutininesterasefus
protein
minor
surfac
glycoprotein
surfac
glycoprotein
form
order
hexagon
array
underneath
viral
membran
tightli
bind
vrnp
consist
rna
strand
usual
singl
strand
certain
case
doubl
strand
wrap
around
np
nep
termin
polymeras
ternari
complex
pa
genom
small
kilobas
contain
seven
eight
piec
segment
negativesens
rna
eight
segment
iav
influenza
b
seven
influenza
c
piec
rna
contain
either
one
two
gene
nucleotid
genom
code
least
protein
hemagglutinin
ha
kda
na
kda
np
kda
kda
kda
nonstructur
protein
type
kda
nonstructur
protein
type
also
known
nep
nuclear
export
protein
kda
pa
kda
polymeras
basic
type
kda
kda
polymeras
basic
type
kda
particular
segment
code
ternari
polymeras
complex
pa
respect
segment
ha
segment
na
segment
np
segment
matrix
protein
segment
nonstructur
protein
basi
gene
structur
segment
divid
three
class
intronless
introncontain
unsplic
introncontain
splice
basi
kinet
gene
express
classifi
earli
segment
unsplic
segment
transcript
late
segment
splice
segment
class
usual
structur
functionalkinet
classif
correspond
moreov
presenc
overlap
gene
differ
splice
mechan
may
give
rise
accessori
protein
pax
discov
character
recent
anoth
accessori
protein
orf
predict
viral
proteom
thu
reveal
unexpect
dynam
complex
matsuoka
coll
design
comprehens
map
influenza
interact
term
flumap
contain
factor
reaction
april
first
import
event
infect
human
attach
influenza
virion
apic
cell
surfac
event
known
also
viru
adsorpt
inde
entri
influenza
viru
target
cell
essenti
process
wherebi
viral
genom
deliv
extracellular
virion
site
transcriptionrepl
cell
nucleu
phase
thank
surfac
glycoprotein
ha
viru
interact
link
sialic
acid
receptor
physicochem
conform
receptor
ident
differ
speci
anim
human
seal
bird
pig
hors
etc
natur
reservoir
viru
vast
major
human
receptor
locat
upper
respiratori
tract
man
also
possess
receptor
typic
bird
locat
deep
respiratori
tract
ha
homotrimer
integr
type
membran
cylind
like
glycoprotein
approxim
nanometr
long
ha
monom
synthes
precursor
contain
hydrophob
signal
sequenc
translat
glycosyl
cleav
two
smaller
subunit
name
kda
kda
link
disulfid
bridg
subunit
character
long
central
connect
membran
surmount
spheric
head
contain
sialic
acid
bind
site
receptor
bind
site
rbss
also
known
receptor
bind
pocket
rbp
apolar
domain
near
cleavag
site
known
fusion
peptid
sinc
character
domain
highli
conserv
ntermin
residu
helicalhairpin
structur
consist
two
tightlypack
helic
fundament
induc
neg
curvatur
fusogen
conform
ha
least
eighteen
ha
subtyp
subdivid
two
group
group
compris
waterfowl
last
two
recent
isol
bat
guatemala
peru
group
compris
howev
recent
experi
prove
viru
also
enter
cell
whose
surfac
complet
deplet
sialic
acidbas
glycoprotein
glycolipid
seem
suggest
altern
entri
rout
inde
bind
sialic
acid
receptor
still
unknown
entri
essenti
receptormedi
endocytosi
though
altern
uptak
pathway
name
macropinocytosi
quit
recent
discov
receptormedi
endocytosi
cme
mediat
lipid
raft
cde
nonclathrin
noncaveola
endocytosi
cme
common
pathway
virion
intern
clathrin
triskelion
made
three
heavi
chain
constitut
backbon
polyhedr
structur
three
light
chain
fine
tune
assembl
disassembl
triskelion
adaptor
protein
epsin
recogn
specif
intern
signal
locat
cargo
receptor
take
part
format
clathrinco
pit
ccp
caveola
small
flasklik
infold
membran
high
level
cholesterol
glycosphingolipid
caveolin
integr
membran
scaffold
structur
remain
entri
rout
investig
less
clathrin
caveolaeindepend
endocytosi
rasphosphoinositid
signal
pathway
may
play
major
role
inact
complex
heterodim
move
plasma
membran
src
homolog
domain
engag
phosphotyrosin
residu
present
receptorassoci
protein
caus
molecular
rearrang
complex
way
enzymat
activ
recruit
produc
intracellular
second
messeng
ptdin
phosphatidylinositol
trisphosph
ptdin
phosphatidylinositol
bisphosph
subsequ
sever
effector
protein
pleckstrin
homolog
ph
domain
mediat
array
differ
signal
cascad
name
activ
akt
mtor
mammalian
target
rapamycin
pkc
protein
kinas
c
pten
phosphatas
tensin
homolog
pathway
macropinocytosi
activ
cell
growth
factor
epiderm
growth
factor
egf
nerv
growth
factor
ngf
induc
phorbol
ester
macropinocytosi
kinas
type
cholesterol
actindepend
sinc
extens
reorgan
plasma
membran
impli
energi
mechan
nah
exchang
nhe
activ
also
pathogen
ebolaviru
arenaviru
adenoviru
hpv
human
papillomaviru
hiv
human
immunodefici
viru
escherichia
coli
trypanosoma
cruzi
vaccinia
viru
african
swine
fever
viru
rsv
respiratori
syncyti
viru
hcv
hepat
c
viru
among
other
use
macropinocytosi
addit
entri
pathway
differ
rout
cme
cde
nonclathrin
noncaveola
endocytosi
macropinocytosi
result
differ
intern
yield
may
relat
differ
degre
virul
pathogen
influenza
strain
attach
respiratori
cell
surfac
influenza
viru
alreadi
mention
penetr
cell
one
mechan
final
result
virion
intern
endosom
compart
accord
previou
rout
virion
packag
ccp
clathrinco
vesicl
ccv
caveosom
macropinosom
subsequ
process
earli
endosom
ee
late
endosom
le
endosom
traffick
usual
follow
influenza
viru
uptak
virion
taken
rab
lysosomalassoci
membran
protein
posit
endosom
rab
guanosin
triphosphatas
gtpase
respons
process
traffick
fusion
ee
le
respect
lamp
seri
protein
isoform
current
known
name
known
also
dclamp
involv
endosom
matur
moreov
express
found
predict
host
respons
influenza
belong
cullinringligas
famili
crl
function
scaffold
protein
bricabrac
tramtrack
broadcomplex
btb
ubiquitin
ligas
complex
involv
le
matur
cargo
traffick
endosom
traffick
complex
multifacet
process
divid
three
stage
stage
actindepend
stage
ii
dynein
microtubul
depend
stage
iii
microtubuledepend
order
viru
emerg
endosom
ribonucleoprotein
rnp
releas
cytosol
envelop
must
fuse
endosom
membran
part
lifecycl
viru
requir
acid
lumen
endosom
decreas
ph
valu
process
crucial
role
play
act
ion
channel
therebi
allow
acidif
interior
viru
also
alter
conform
result
chang
curvatur
viral
envelop
lead
two
import
event
name
dissoci
protein
rnp
dramat
chang
conform
ha
expos
fusion
peptid
peptid
may
allow
fusion
viral
envelop
endosom
membran
releas
rnp
cytoplasm
cleavag
ha
occur
proteas
enzymat
action
proteas
caus
cleavag
ha
wide
distribut
throughout
human
bodi
precis
role
play
cut
ha
exactli
known
nevertheless
proteas
known
belong
two
main
class
name
trypsinlik
enzym
furinlik
serin
enzym
enzym
produc
cell
particularli
respiratori
system
presenc
inflamm
proinflammatori
cytokin
chemokin
neutrophil
etc
releas
rnp
cytosol
also
enabl
host
aggresom
process
machineri
made
dynein
dynactin
myosin
ii
molecul
pathway
could
take
part
process
simpl
ion
channel
inde
play
multifacet
role
entir
viral
lifecycl
mechan
proton
permeat
conduct
acidif
crucial
differ
step
activ
viru
endocytosi
low
endosom
ph
rang
activ
channel
prior
hamedi
fusion
favour
dissoci
protein
vrnp
therebi
facilit
entri
rnp
nucleu
fundament
genom
unpack
releas
viral
rna
viral
uncoat
moreov
enabl
viral
rna
packag
facilit
virion
scission
bud
viral
matur
assembl
replic
infect
transport
cell
surfac
transgolgi
network
tgn
membran
act
protonleak
channel
prevent
activ
de
novo
synthes
ha
regul
ph
golgi
apparatu
host
cell
equilibr
ph
ph
viral
interior
inde
elev
way
low
ph
would
caus
conform
rearrang
ha
whose
intracellular
cleavag
would
prematur
inactiv
new
influenza
viral
progeni
togeth
protein
ha
could
play
addit
role
finetun
apoptosi
infect
cell
thu
favour
viral
replic
involv
sever
biolog
task
mrna
splice
translat
cell
surviv
immun
defenc
particular
far
type
interferon
ifni
mediat
respons
concern
interact
pactprkra
protein
activ
interferon
induc
protein
kinas
protein
kinas
interferoninduc
doubl
strand
rna
depend
activ
import
cofactor
ifni
respons
elicit
viral
rnasensor
rigi
retino
acid
induc
gene
therefor
block
pactrigimedi
activ
ifni
moreov
bind
latent
protein
kinas
pkr
protein
kinas
r
also
known
protein
kinas
rnaactiv
interferoninduc
doublestrand
rnaactiv
protein
kinas
eukaryot
translat
initi
factor
kinas
whose
activ
would
inhibit
viral
protein
translat
synthesi
also
tripartit
motifcontain
protein
recent
shown
interact
array
host
protein
receptor
mhc
class
hlab
cathepsin
b
ubiquitin
adenosin
deaminas
act
rna
regard
ion
channel
activ
heart
mechan
hxxxw
motif
inner
transmembran
tm
residu
hxxxw
motif
histidin
put
act
ph
sensor
ph
low
proton
imidazol
ring
destabil
tm
pack
electrostat
repuls
tryptophan
act
primari
gate
rotat
becom
unlock
aspart
acid
channel
lock
parallel
axi
pore
make
proton
flow
contrast
valin
act
secondari
gate
socal
valin
valv
import
confirm
recent
multiscal
simul
carri
liang
coll
basi
exact
role
histidin
tetrad
two
model
propos
shutter
model
biproton
charg
histidin
chang
proton
flux
proton
diffus
coupl
water
wire
via
grotthuss
mechan
shuttl
model
proton
statu
histidin
subject
chang
excess
proton
transfer
howev
exact
mechan
highli
select
transport
proton
known
acidif
enhanc
viral
activ
cascad
next
event
replic
import
rnp
nucleu
traffick
rnp
cytoplasm
achiev
extrem
rapidli
mean
mechan
diffus
without
intervent
microtubul
intermedi
filament
actin
filament
nuclear
pore
complex
npc
import
compon
npc
nucleoporin
nuclear
transport
factor
belong
socal
subcomplex
belong
subcomplex
compon
magoh
aladin
tpr
transloc
promot
region
ejc
exon
junction
complex
nucleoporin
like
protein
type
nuclear
envelop
pore
membran
protein
type
rnp
reach
nuclear
membran
nuclear
import
mediat
bind
nucleoprotein
alpha
importin
bind
simultan
importin
must
interact
pa
affect
interact
rnp
importin
specif
subunit
pa
import
ran
karyopherin
also
known
importin
importin
whilst
subunit
import
importin
importin
np
import
importin
molecul
take
part
nuclear
import
nucleu
importin
detach
rnp
although
clear
mechan
known
molecular
level
dissoci
rnp
occur
separ
importin
thu
spread
rnp
nucleoplasm
transcript
replic
initi
transcript
replic
viral
nucleic
acid
fulli
understood
howev
phenomena
involv
coordin
differenti
rna
np
rdrp
activ
packag
consist
genom
segment
srna
unit
trimer
polymeras
nucleoprotein
elementari
replic
unit
influenza
viru
vrnp
therefor
nucleoplasm
vrnp
need
trigger
first
round
replic
cycl
ie
copi
genom
inform
onto
mrna
subsequ
mrna
export
occur
cytoplasm
influenza
polymeras
heterotrimer
kd
complex
play
central
role
viral
lifecycl
directli
respons
rna
synthesi
viral
replic
transcript
moreov
recruit
host
factor
pa
subunit
interact
host
factor
minichromosom
mainten
complex
mcm
put
dna
helicas
subunit
bind
host
rna
cap
triphosph
gtp
support
endonucleas
activ
pa
order
snatch
cap
host
premrna
moreov
interact
acetylcoa
found
eukaryot
histon
acetyltransferas
hat
viral
mrna
synthesi
initi
cisact
viral
rna
polymeras
part
vrnp
structur
bound
vrna
promot
howev
mrna
abl
translat
genet
messag
effici
inde
need
cap
specif
viru
must
use
premrna
cell
purpos
coordin
process
mediat
pa
cellular
polymeras
ii
pol
ii
necessari
briefli
bind
mrna
cellular
pol
ii
pa
mean
endonucleas
mechan
gener
cappedmrna
translat
ribosom
level
accord
model
propos
fodor
transact
polymeras
activ
necessari
vrna
replic
neg
polar
vrna
posit
rna
crna
must
synthes
mrna
templat
replic
vrna
could
perform
transact
rna
polymeras
may
distinct
polymeras
packag
rnp
variou
hypothes
formul
regard
protein
instanc
np
trigger
transact
polymeras
although
assumpt
contradict
studi
shown
viral
replic
absenc
np
presenc
newli
synthesis
np
appear
import
stabil
length
segment
viral
rna
furthermor
studi
suggest
nep
could
regul
viral
rna
synthesi
import
newli
synthesis
nucleoprotein
polymeras
also
import
order
assembl
nucleoprotein
negativesens
viral
rna
event
complet
understood
requir
coordin
interact
nuclear
localis
signal
nlss
pa
np
importin
addit
recent
research
demonstr
np
play
major
role
assembl
vrnp
interact
polymeras
subunit
involv
nuclear
cytoplasmat
transport
vrnp
specif
np
oligomer
ring
structur
interact
viral
rna
segment
also
polymeras
trimer
latter
interact
allow
viral
rna
twist
doubl
helix
polymeras
complex
one
termin
loop
rna
anoth
termin
progress
infect
requir
coordin
twoway
flow
protein
synthes
cytoplasm
instanc
protein
np
viral
rna
replic
nucleu
way
rnp
full
vrna
np
pa
nonstructur
protein
reconstitut
nucleu
transcript
factori
made
compon
sfpqpsf
splice
factor
prolineglutamin
rich
though
entir
molecular
anatomi
known
alreadi
mention
splice
mechan
crucial
increas
dynam
complex
influenza
proteom
specif
spliceosom
complex
interact
respons
splice
compon
spliceosom
complex
ejc
sr
serin
argininerich
protein
premrna
splice
factor
type
altern
splice
factor
hnrnp
k
heterogen
nuclear
ribonucleoprotein
k
transcript
replic
enhanc
activ
cascad
via
subsequ
one
mechan
small
protein
capabl
pass
nuclear
pore
easili
rnp
complex
export
cytoplasm
export
machineri
factori
made
sever
compon
nuclear
rna
export
factor
type
cbc
nuclear
capbind
complex
particular
kda
subunit
refali
trex
yboxbind
protein
type
exportin
type
regul
chromosom
condens
type
chromodomain
helicas
dnabind
protein
type
atpdepend
rna
helicas
heat
shock
cognat
protein
among
other
briefli
two
main
export
rout
describ
pathway
rnp
export
via
whilst
ha
na
transport
pathway
includ
ran
among
other
translat
protein
transport
golgi
network
modifi
modif
glycosyl
ha
na
palmitoylationsacyl
ha
phosphoryl
sumoyl
np
nep
sumo
small
ubiquitinlik
modifi
type
essenti
step
product
function
activ
viral
protein
task
perform
kinas
cyclindepend
kinas
cdk
extracellular
signalregul
kinas
erk
protein
retrograd
transport
copi
transgolgi
apparatu
cisgolgi
er
qualiti
protein
fold
correct
posttransl
process
check
protein
malectin
calnexin
calreticulin
export
rnp
favour
infect
progress
result
activ
mechan
spontan
cell
death
apoptosi
activ
caspas
alter
nuclear
membran
activ
caspas
increas
pervious
nuclear
pore
inde
caspas
signal
pathway
play
import
role
activ
replic
propag
pathogen
influenza
viru
therefor
relat
sever
influenza
symptom
clinic
burden
viru
fine
tune
modul
host
cellular
protein
involv
process
regul
control
induct
apoptosi
unit
rnp
releas
nucleu
concentr
perinuclear
cytoplasm
particularli
region
centr
organ
microtubul
mtoc
subsequ
area
recycl
endosom
re
interact
re
allow
rnp
interact
better
network
microtubul
thu
orient
travel
toward
cell
membran
export
rnp
complic
mechan
requir
wellsynchron
time
result
accumul
rnp
apic
surfac
cell
late
stage
viral
multipl
late
stage
viral
replic
accumul
ha
molecul
cell
membran
probabl
activ
mitogenactiv
protein
kinas
mapk
increas
export
rnp
still
unknown
mechan
orient
toward
apic
surfac
cell
subsequ
unit
rnp
contain
one
eight
segment
viral
genom
particularli
import
differ
segment
assembl
properli
viral
rna
mediat
process
hierarch
assembl
signal
mechan
infect
progress
apic
membran
becom
rich
viral
protein
togeth
initi
bud
viru
around
complex
rnp
region
membran
extrud
ha
na
protein
concentr
viral
protein
deliv
plasma
membran
assembl
hrb
hiv
revbind
protein
play
import
role
ha
abl
initi
process
bud
complet
requir
mediat
na
protein
also
import
consid
format
posit
curvatur
cell
membran
suitabl
assembl
unit
rnp
move
toward
distal
part
viral
bud
properli
wrap
viral
envelop
bud
process
progress
stalk
gener
hold
virion
cell
viral
envelop
must
detach
cell
membran
protein
appear
crucial
process
inde
capabl
gener
posit
curvatur
membran
necessari
order
enabl
spheric
virion
split
howev
viru
yet
free
bound
cell
bind
ha
molecul
unit
sialic
acid
membran
surfac
na
molecul
must
therefor
detach
sialic
acid
cell
surfac
order
accomplish
viral
bud
enzymat
mechan
influenza
viru
sialidas
studi
taylor
show
enzym
catalysi
process
particularli
complex
consist
four
step
first
step
distort
chair
conform
pseudoboat
conform
sialosid
bind
sialidas
second
step
lead
sialosyl
cation
oxocarboc
intermedi
third
step
format
fourth
step
involv
mutarot
subsequ
releas
thermodynamicallyst
final
step
lead
sialic
acid
hydrolysi
current
isoform
na
known
recent
isol
bat
abl
cleav
sialic
acid
precis
role
mechan
still
unknown
na
classifi
two
group
group
group
base
upon
primari
sequenc
group
na
contain
form
amino
acid
expos
pocket
near
activ
catalyt
site
wherea
group
na
lack
caviti
bud
occur
via
independ
pathway
amantadin
rimantadin
fig
first
gener
influenza
antivir
agent
amantadin
deriv
hydrocarbon
tricyclo
decan
amantadin
administ
either
hydrochlorid
deriv
symmetrel
mg
tablet
syrup
effect
deriv
rimantadin
adamantanemethylamin
hydrochlorid
flumadin
high
concentr
amantadin
rimantadin
nonspecif
rais
ph
within
cellular
endosom
thu
inhibit
retard
acidinduc
conform
chang
viral
ha
low
concentr
amantadin
rimantadin
specif
inhibit
ionchannel
activ
protein
cross
brainblood
barrier
present
cerebrospin
fluid
csf
concentr
around
serum
level
amantadin
also
use
treat
parkinson
diseas
depress
obsessivecompuls
disord
ocd
huntington
diseas
attent
deficit
hyperact
disord
adhd
neuropsychiatr
diseas
cocain
abus
depend
hcv
creutzfeldt
jakob
diseas
borna
diseas
herp
post
herp
zoster
neuralgia
phn
varieti
use
seem
suggest
amantadin
besid
block
channel
act
array
receptor
dopaminerg
receptor
noradrenerg
serotoninerg
cholinerg
nmethyldaspart
nmda
receptor
rapidli
adsorb
excel
bioavail
profil
usual
rang
drug
reach
peak
plasma
level
within
hour
plasma
elimin
halflif
h
patient
normal
renal
function
plasma
protein
bind
drug
poorli
metabol
wide
distribut
almost
complet
excret
via
glomerular
filtrat
tubular
secret
impli
dose
adjust
administ
patient
renal
failur
elderli
reduc
daili
dose
mg
instead
mg
act
muscarin
receptor
patient
may
experi
antimuscarin
advers
effect
orthostat
hypotens
gastrointestin
discomfort
nausea
vomit
anorexia
congest
heart
failur
moreov
amantadin
central
nervou
system
cn
stimulatori
properti
adult
may
complain
confus
disorient
jitteri
anxieti
mood
disord
slur
speech
insomnia
ataxia
tremor
rare
nightmar
oculogyr
episod
symptom
usual
common
drug
use
differ
week
prophylact
purpos
instead
use
treatment
less
week
better
toler
rare
case
seizur
hallucinosishallucin
coma
acut
psychosi
cardiac
arrhythmia
may
occur
usual
patient
underli
psychiatr
comorbid
adult
respiratori
distress
syndrom
ard
rare
anecdot
report
cross
placenta
present
breast
milk
teratogen
least
anim
even
though
safeti
establish
pregnant
women
precaut
sake
belong
class
c
pregnanc
recogn
one
risk
factor
catch
influenza
untoward
outcom
higher
morbid
hospit
mortal
rate
benefit
adamantan
also
children
elder
effect
prevent
treat
shorten
durat
influenza
appear
limit
accord
recent
systemat
review
rimantadin
administ
mg
tablet
reach
peak
plasma
concentr
hour
plasma
halflif
long
hour
rimantadin
metabol
amantadin
secret
unchang
plasma
protein
bind
rimantadin
character
lower
rate
adr
compar
amantadin
better
toler
children
elderli
unfortun
use
inhibitor
limit
emerg
drugresist
strain
influenza
virus
mutat
porefac
residu
mutat
close
interhel
residu
locat
ntermin
half
channel
mutat
far
interhel
residu
far
locat
ctermin
half
channel
recent
time
wide
use
antivir
influenza
inhibitor
neuroaminidas
name
oseltamivir
zanamivir
fig
chemic
point
view
na
inhibitor
classifi
sialic
acid
deriv
deriv
benzoic
acid
deriv
cyclohexen
deriv
cyclopentan
deriv
pyrrolidin
deriv
natur
product
first
na
inhibitor
repres
first
chemic
class
unsatur
syalic
acid
analog
dana
fana
initi
describ
meindl
tuppi
na
homotetramer
enzym
kda
essenti
reproduct
influenza
viru
inde
exert
least
three
crucial
action
first
neuraminidas
free
viru
respiratori
mucu
allow
reach
cell
respiratori
mucosa
easili
coordin
action
ha
na
requir
phase
viral
bud
final
na
requir
order
releas
viru
cell
surfac
cut
molecul
sialic
acid
still
anchor
viru
cell
surfac
mean
ha
complet
replic
cycl
action
also
facilit
separ
selfaggreg
virion
viral
progeni
burnet
coll
first
idea
inhibitor
na
could
effect
antivir
agent
crystal
structur
na
complex
neuroamin
acid
defin
coleman
possibl
von
itzstein
synthes
neuroamin
acid
deriv
enhanc
affin
influenza
na
compound
zanamivir
mechan
action
ident
oseltamivir
character
fact
molecul
mimic
sialic
acid
thu
enter
competit
acid
revers
bind
molecul
viral
na
zanamivir
design
concentr
local
respiratori
tract
oseltamivir
design
high
bioaval
concentr
oral
administr
inde
oseltamivir
well
absorb
gastrointestin
tract
rapidli
metabolis
activ
oseltamivir
carboxyl
phosphat
liver
hepat
carboxylesteras
activ
metabolit
distribut
throughout
bodi
includ
upper
lower
respiratori
tract
middl
ear
tracheal
line
nasal
mucosa
lung
plasma
halflif
vari
hour
hour
carboxyl
form
oseltalmivir
extens
metabol
oseltamivir
zanamivir
result
compar
term
clinic
profil
superior
adamantan
regard
clinic
effect
two
drug
recent
metaanalysi
jefferson
et
al
reveal
drug
modest
therapeut
effect
healthi
adult
prophylact
treatment
either
zanamivir
oseltamivir
effect
prevent
diseas
zanamivir
suppli
rotadisk
four
blister
contain
mg
powder
five
rotadisk
packag
diskhal
inhal
devic
oseltamivir
avail
mg
capsul
oral
suspens
contain
mgml
oseltamivir
phosphat
adr
usual
nausea
vomit
recent
cn
toxic
infant
younger
one
year
age
report
adjust
necessari
subject
suffer
renal
failur
adjust
need
patient
hepat
failur
mild
obes
oseltamivir
administ
pregnant
women
major
current
circul
influenza
viral
strain
resist
amantadan
resist
strain
type
b
virus
oseltamivir
zanamivir
low
reason
us
cdc
recommend
use
treatment
prevent
season
pandem
influenza
two
analogu
zanamivir
oseltamivir
current
licens
japan
asian
countri
peramivir
laninamivir
octano
hydrat
cs
fig
former
administ
intraven
poor
bioavail
licens
japan
south
korea
temporarili
approv
emerg
use
usa
pandem
latter
drug
promis
longact
inhibitori
effect
inavir
launch
japan
octob
dri
powder
inhal
prodrug
convert
airway
laninamivir
activ
nai
retain
high
concentr
least
day
singl
inhal
mg
drug
oral
bioavail
commonli
report
adr
psychiatr
gastrointestin
cn
disord
singl
inhal
dose
make
inavir
quit
conveni
drug
even
though
children
young
adolesc
could
inhal
properli
consid
compound
target
transcript
replic
vrna
one
first
develop
drug
ribavirin
fig
ribavirin
also
known
trade
name
virazol
guanosin
nucleosid
analog
triazol
mechan
action
complet
known
howev
inosin
dehydrogenas
impdh
appear
princip
target
molecul
inhibit
diminish
intracellular
concentr
gtp
triphosph
would
stop
viral
protein
synthesi
limit
vrna
replic
crotti
et
al
also
demonstr
ribavirin
vrna
lethal
mutagen
resembl
guanosin
adenosin
caus
mutat
rna
replic
howev
need
high
dose
drug
good
clinic
result
limit
use
ribavirin
antiinfluenza
drug
recent
revis
literatur
chantack
et
al
suggest
conclus
result
benefici
use
virazol
treatment
influenza
ribavirin
administ
oral
aerosol
rare
intraven
rout
adr
depend
administr
rout
extravascular
haemolyt
anemia
drug
deliv
intraven
bronchospasm
aerosol
sever
potenti
effect
drug
act
ha
inhibitor
howev
one
medic
small
indol
deriv
arbidol
arb
umifenovir
fig
dimethylamino
methyl
phenylthio
methyl
monohydr
licens
arb
creat
center
drug
chemistri
moscow
licens
russia
year
ago
sinc
use
china
prophylaxi
treatment
pneumonia
caus
influenza
virus
b
arb
probabl
exert
multipl
antivir
action
direct
virucid
effect
block
viru
level
cellentri
attach
intern
impair
viral
replic
abil
bind
protein
lipid
sever
studi
demonstr
arb
also
effect
envelop
nonenvelop
virus
hepat
b
viru
hbv
hcv
rsv
picornaviru
rhinoviru
polioviru
coxsackieviru
parainfluenza
type
well
avian
coronaviru
infecti
bronchiti
viru
chikungunya
viru
reoviru
hantaan
viru
vesicular
stomat
viru
vsv
marek
diseas
viru
avian
oncogen
herpesviru
metabol
liver
redistribut
bodi
tissu
princip
biotransform
pathway
includ
sulfoxid
dimethylamin
ndemethyl
glucuronid
sulfat
conjug
major
metabolit
sulfinylarbidol
follow
unmetabol
arbidol
ndemethylsulfinylarbidol
sulfonylarbidol
major
isoform
involv
arb
metabol
wherea
flavincontain
monooxygenas
fmo
play
minor
role
plasma
halflif
long
hour
recent
decad
antivir
drug
influenza
viru
infect
avail
limit
use
human
anim
outbreak
inde
antivir
drug
use
season
pandem
outbreak
usual
administ
monotherapi
sometim
uncontrol
manner
farm
anim
led
emerg
viral
strain
resist
especi
compound
amantadan
famili
reason
particularli
import
develop
new
antivir
drug
influenza
virus
inde
although
vaccin
current
effect
mean
mitig
effect
influenza
epidem
delay
spread
new
pandem
virus
maintain
advisori
committe
immun
practic
acip
antivir
drug
use
allow
manufactur
prepar
larg
quantiti
pandem
vaccin
addit
antivir
drug
particularli
valuabl
complic
case
influenza
particularli
hospit
patient
individu
risk
elderli
patient
chronic
respiratori
diseas
case
would
particularli
desir
antivir
administ
appropri
manner
